These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9343796)

  • 1. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.
    Johannesson M; Meltzer D; O'Conor RM
    Med Decis Making; 1997; 17(4):382-9. PubMed ID: 9343796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K; Mörk AC; Willers S; Lindgren B
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.
    Zethraeus N; Ström O; Borgström F; Kanis JA; Jönsson B
    Osteoporos Int; 2008 Jun; 19(6):819-27. PubMed ID: 18071650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus.
    Meltzer D; Egleston B; Stoffel D; Dasbach E
    Med Care; 2000 Jun; 38(6):679-85. PubMed ID: 10843315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
    Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
    Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.
    Chang RW; Pellisier JM; Hazen GB
    JAMA; 1996 Mar; 275(11):858-65. PubMed ID: 8596224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating mild to moderate hypertension: cost-effectiveness and policy implications.
    Kawachi I; Malcolm LA
    J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S126-8. PubMed ID: 1708013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of the Chlamydia Monday--a community-based intervention to decrease the prevalence of chlamydia in Sweden.
    Deogan CL; Bocangel MK; Wamala SP; Månsdotter AM
    Scand J Public Health; 2010 Mar; 38(2):141-50. PubMed ID: 20064921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost effectiveness of single-level instrumented posterolateral lumbar fusion at 5 years after surgery.
    Glassman SD; Polly DW; Dimar JR; Carreon LY
    Spine (Phila Pa 1976); 2012 Apr; 37(9):769-74. PubMed ID: 20489676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G; Burke TA; Carides G
    J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
    Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
    Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost effectiveness of hypertension treatment in Sweden.
    Johannesson M
    Pharmacoeconomics; 1995 Mar; 7(3):242-50. PubMed ID: 10155314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
    Zeliadt SB; Etzioni RD; Penson DF; Thompson IM; Ramsey SD
    Am J Med; 2005 Aug; 118(8):850-7. PubMed ID: 16084177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.